NYSE$HIMS
Hims & Hers Health Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Hims & Hers experienced growth and profitability in Q3 2024.
Hims & Hers Health, Inc. reported a strong third quarter in 2024 with revenue of $401.6 million, up 77% year-over-year. The company achieved a net income of $75.6 million and Adjusted EBITDA of $51.1 million. Subscriber base grew to 2.0 million, a 44% increase year-over-year. The company also raised its full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million.
- Revenue increased by 77% year-over-year, reaching $401.6 million in Q3 2024.
- Net income was $75.6 million, including a $60.8 million tax benefit.
- Adjusted EBITDA was $51.1 million, compared to $12.3 million in the same quarter last year.
- The subscriber base grew to 2.0 million, reflecting a 44% year-over-year increase.
Headline financials
Revenue & EPS history
Hims & Hers · Revenue · Quarterly
$402M
Revenue by segment
Hims & Hers · $227M total across 2 segments · Q3 2023
- Online Revenue$220M+57.1%96.9%
- Wholesale Revenue$7.03M+39.1%3.1%
Forward guidance
Hims & Hers provided revenue and Adjusted EBITDA guidance for Q4 2024 and full year 2024.
Tailwinds
- Revenue of $465 million to $470 million is expected for the fourth quarter of 2024.
- Adjusted EBITDA of $50 million to $55 million is anticipated for Q4 2024, reflecting an Adjusted EBITDA margin of 11% to 12%.
- Full year 2024 revenue is projected to be between $1.460 billion and $1.465 billion.
- Adjusted EBITDA for the full year 2024 is expected to range from $173 million to $178 million, with an Adjusted EBITDA margin of 12.
- Company is focused on driving top-line growth and profitability
Headwinds
- Guidance constitutes forward-looking statements and actual results may differ materially.
- The company cannot predict with reasonable certainty the ultimate outcome of certain components of reconciliations.
- Market-related assumptions are not within their control.
- The company is unable to assess the probable significance of the unavailable information.
- Future developments affecting the company may not be those that they have anticipated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+2.5%
Avg return
Earnings day
+3.8%
Avg return
5 days after
+11.7%
Avg return
30 days after
50%
13 / 26 earnings
Positive
+41.1%
Q4 2023
Best reaction
-22.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | -11.4% | -1.8% | |
| Q4 2025 | -2.8% | -6.4% | +34.5% | |
| Q3 2025 | -3.6% | -7.6% | -9.8% | |
| Q1 2025 | +18.5% | +24.1% | +26.0% | |
| Q4 2024 | -22.3% | -12.1% | -37.8% | |
| Q3 2024 | +1.4% | +15.0% | +66.6% | |
| Q2 2024 | -4.0% | -9.2% | -16.9% | |
| Q1 2024 | +9.7% | +9.1% | +93.2% | |
| Q4 2023 | +41.1% | +37.8% | +65.3% | |
| Q3 2023 | +7.6% | +5.1% | +37.3% | |
| Q2 2023 | -8.7% | -11.7% | -15.2% | |
| Q1 2023 | -11.5% | -10.2% | -23.9% | |
| Q4 2022 | +15.4% | +6.0% | +2.7% | |
| Q3 2022 | +30.1% | +37.2% | +64.7% | |
| Q2 2022 | -3.4% | +9.2% | -0.6% | |
| Q1 2022 | -13.0% | -13.5% | +5.3% | |
| Q4 2021 | +8.0% | +20.5% | +19.8% | |
| Q3 2021 | -7.0% | -1.3% | -26.3% | |
| Q2 2021 | +7.0% | -4.7% | +11.1% | |
| Q1 2021 | +13.7% | +44.9% | +33.1% | |
| Q2 2020 | -8.4% | -7.2% | -21.9% | |
| Q4 2020 | -7.5% | -15.4% | -21.3% | |
| Q3 2020 | +0.1% | +0.0% | +17.5% | |
| Q1 2020 | -0.7% | -0.5% | +0.1% | |
| Q4 2019 | +1.4% | +2.1% | +2.2% | |
| Q3 2019 | +0.0% | +0.3% | -0.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro